{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:17:09Z","timestamp":1762867029634},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Nederlandse Hartstichting","award":["2007.B138"],"award-info":[{"award-number":["2007.B138"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0168273","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T13:40:08Z","timestamp":1486129208000},"page":"e0168273","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Platelet full length TFPI-\u03b1 in healthy volunteers is not affected by sex or hormonal use"],"prefix":"10.1371","volume":"12","author":[{"given":"Kristien","family":"Winckers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilman M.","family":"Hackeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,2,3]]},"reference":[{"key":"ref1","first-page":"90","article-title":"Tissue factor pathway inhibitor","volume":"74","author":"GJ Broze Jr","year":"1995"},{"key":"ref2","first-page":"233","article-title":"The haemostatic role of tissue factor pathway inhibitor","volume":"28","author":"JT Crawley","year":"2008"},{"key":"ref3","first-page":"262","article-title":"Tissue factor pathway inhibitor: structure-function","volume":"17","author":"GJ Broze Jr","year":"2012"},{"key":"ref4","first-page":"518","article-title":"Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor","volume":"338","author":"TJ Girard","year":"1989"},{"key":"ref5","first-page":"266","article-title":"The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa","volume":"108","author":"S Peraramelli","year":"2012"},{"key":"ref6","first-page":"2004","article-title":"Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa","volume":"79","author":"R Wesselschmidt","year":"1992"},{"key":"ref7","first-page":"3106","article-title":"Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor","volume":"103","author":"TM Hackeng","year":"2006"},{"key":"ref8","first-page":"1344","article-title":"The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition","volume":"116","author":"M Ndonwi","year":"2010"},{"key":"ref9","first-page":"1047","article-title":"Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues","volume":"82","author":"MS Bajaj","year":"1999"},{"key":"ref10","first-page":"551","article-title":"Heterogeneity of plasma tissue factor pathway inhibitor","volume":"5","author":"GJ Broze Jr","year":"1994"},{"key":"ref11","first-page":"387","article-title":"Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples","volume":"78","author":"WF Novotny","year":"1991"},{"key":"ref12","first-page":"713","article-title":"Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients","volume":"2","author":"AK Lindahl","year":"1991"},{"key":"ref13","first-page":"9","article-title":"Expression of tissue factor pathway inhibitor by endothelial cells and platelets","volume":"38","author":"SA Maroney","year":"2008"},{"key":"ref14","first-page":"394","article-title":"Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor","volume":"78","author":"WF Novotny","year":"1991"},{"key":"ref15","first-page":"2020","article-title":"Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor","volume":"72","author":"WF Novotny","year":"1988"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2009.021923","article-title":"Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from mixed type I\/III families","author":"E Castoldi","year":"2010"},{"key":"ref17","first-page":"4387","article-title":"Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis","volume":"101","author":"A Dahm","year":"2003"},{"key":"ref18","first-page":"175","article-title":"Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives","volume":"60","author":"GM Harris","year":"1999"},{"key":"ref19","first-page":"606","article-title":"The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI","volume":"109","author":"M Raps","year":"2013"},{"key":"ref20","first-page":"750","article-title":"Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals","volume":"8","author":"LF Maurissen","year":"2010"},{"key":"ref21","first-page":"1150","article-title":"Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool","volume":"88","author":"MC Thomassen","year":"2003"},{"key":"ref22","first-page":"879","article-title":"Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms","volume":"115","author":"C Duckers","year":"2010"},{"key":"ref23","first-page":"186","article-title":"Platelet activation and blood coagulation","volume":"88","author":"JW Heemskerk","year":"2002"},{"key":"ref24","first-page":"169","article-title":"Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-alpha but not for cell surface-associated tissue factor pathway inhibitor","volume":"34","author":"JP Wood","year":"2014"},{"key":"ref25","first-page":"944","article-title":"Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice","volume":"90","author":"ZF Huang","year":"1997"},{"key":"ref26","first-page":"203","article-title":"Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis","volume":"81","author":"RA Ariens","year":"1999"},{"key":"ref27","first-page":"787","article-title":"Schneider Bet al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism","volume":"94","author":"M Hoke","year":"2005"},{"key":"ref28","first-page":"2208","article-title":"Impaired tissue factor pathway inhibitor function is associated with recurrent venous thromboembolism in patients with first unprovoked deep venous thrombosis","volume":"10","author":"K Winckers","year":"2012"},{"key":"ref29","first-page":"207","article-title":"Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology","volume":"104","author":"NA Zakai","year":"2010"},{"key":"ref30","first-page":"2331","article-title":"New insights into the mechanisms of venous thrombosis","volume":"122","author":"N Mackman","year":"2012"},{"key":"ref31","first-page":"3927","article-title":"Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia","volume":"109","author":"SA Maroney","year":"2012"},{"key":"ref32","first-page":"1350","article-title":"Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography","volume":"98","author":"SN Tchaikovski","year":"2007"},{"key":"ref33","first-page":"327","article-title":"Oral contraceptives and thrombotic disease: risk of venous thromboembolism","volume":"78","author":"FM Helmerhorst","year":"1997"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0168273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T23:40:57Z","timestamp":1540338057000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0168273"}},"subtitle":[],"editor":[{"given":"Pablo","family":"Garcia de Frutos","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,3]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0168273","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,3]]}}}